Innate Pharma (IPHA) Net Income (2019 - 2025)

Innate Pharma (IPHA) has reported Net Income for 7 consecutive years, with -$56.0 million the latest figure, recorded in Q4 2025.

• Quarterly Net Income rose 0.59% year-over-year to -$56.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$80.2 million (down 615.88% YoY) and the FY2025 annual result came in at -$56.0 million, up 0.59% from the prior year.
• Net Income slipped to -$56.0 million in Q4 2025 per IPHA's latest filing, from -$24.3 million in the prior quarter.
• Over the last five years, Net Income for IPHA reached as high as $56.4 million in Q2 2024 and fell as low as -$66.1 million in Q4 2022.
• A 5-year average of -$16.4 million and a median of -$16.5 million in 2023 frame the typical range for Net Income.
• Annual changes were most pronounced in 2023 — Net Income slumped 3091.78% — and 2024, when it soared 2225.67%.
• Year by year, Net Income stood at -$60.1 million in 2021, then decreased by 10.02% to -$66.1 million in 2022, then soared by 86.97% to -$8.6 million in 2023, then slumped by 553.51% to -$56.3 million in 2024, then climbed by 0.59% to -$56.0 million in 2025.
• According to Business Quant data, Net Income over the past three periods registered -$56.0 million, -$24.3 million, and -$56.3 million for Q4 2025, Q2 2025, and Q4 2024 respectively.